January 22nd 2026 | 8AM - 8PM
The program will include thematic panels and forums covering major topics such as scientific research and innovation, advances in clinical management, and the experiences of the EB community.
Open Forums
Accessible to all participants of the conference. The audience will be encouraged to take part in a lively discussion.
Professional Forums
Educational lessons intended for health care providers working with and/or supporting patients and families in the respective field.
Simultaneous Interpretation
The official language of EB 2026 is English, and the congress will provide simultaneous interpretation (English > Portuguese / English > Spanish) during the sessions.
To access the interpretation, each participant must:
✔️ Bring their own headphones
✔️ Use their mobile phone
✔️ Ensure the device has enough battery to follow the entire program. Tip: also bring a portable charger (power bank).
This measure ensures greater convenience, quality, and accessibility throughout the congress.
start: 8:30
end: 10:15
Location: Theater
5th Session Preclinical studies Part 2
Biofilm and wound infection in Epidermolysis Bullosa
Patient-Derived Samples as a Prerequisite for Pre-Clinical Research
Gene editing for type XVII collagen deficient JEB
Autologous iPSC derived skin grafts for DEB treatment
Prime-edting for treatment of DEB
Splice modulation strategies using antisense oligonucleotides for Recessive Dystrophic Epidermolysis Bullosa
Oral abstract: N-Acetylcysteine as a therapeutic candidate for RDEB wound healing
Evelyng Catalán
Discussion
all speakers
start: 8:30
end: 10:15
Location: Curitiba Room
DEBRA International: High resource groups
To foster growth and sharing of ideas to enable established and potential member DEBRA/EB groups to benchmark, develop and strengthen their organizations. Enhance a strong international network in EB for advocacy, healthcare, social support and national membership needs.
Oral presentation : Living with Dystrophic Epidermolysis Bullosa in Poland First National Assessment of Quality of Life and Clinical Burden
Natalia Bien
start: 10:15
end: 10:40
Coffee Break
start: 10:40
end: 12:40
Location: Theater
6th Session Cancer Therapies
Mechanisms underlying aggressiveness of RDEB-associated cSCCs
Squamous Cell Carcinoma in Chilean EB patients: A retrospective study of 27 years
Using Artificial Intelligence for SCC detection in RDEB
Current treatment standards for EB-SCC treatments
cSCC in Kindler syndrome - underlying pathomechanism
Walking on Glass: Safely Delivering Cancer Therapy in EB
Emerging Therapies for RDEB-SCC: a US Adult EB Clinic Experience
Oral abstract: Towards a minimally invasive diagnostic for early detection of cancer in Recessive Dystrophic
Albert Mellick
Discussion
all speakers
start: 10:40
end: 12:40
Location: Curitiba Room
DEBRA International: Low resource groups
To foster growth and sharing of ideas to enable established and potential member DEBRA/EB groups to benchmark, develop and strengthen their organizations. Enhance a strong international network in EB for advocacy, healthcare, social support and national membership needs.
(moderator)
Dra Florencia Fernandez
(Argentina)
start: 13:00
end: 14:15
Conference Lunch
start: 14:15
end: 15:45
Location: Theater
7ª Session Clinical Trials Part 1, Corrective Therapies
Clinical Trials for RDEB Using Skin Grafts Modified with SIN Retroviral Vectors
Alain Hovnanian
Gene therapies for EB
Clinical trial for treating eye manifestation in DEB patients by delivering COL7A1 gene
Suma krishnan
Oral abstract : COL7A1 c.6527dupC (insC): A translational Journey from early Diagnosis to Prime Editing
Fernando Larcher
Oral abstract: Highly efficient correction of recurrent pathogenic variants in COL7A1 using Cytosine or Adenine Base editing to treat recessive dystrophic epidermolysis bullosa
Araksya Izmiryan
Oral abstract: Development of a Dual CRISPRCas9 Nickase Strategy for COL7A1 Correction in a Prevalent Brazilian Pathogenic Variant of Recessive Dystrophic Epidermolysis Bullosa
Laurent Ketlen Leão Viana
Discussion
all speakers
start: 15:45
end: 16:05
Coffee Break
start: 16:05
end: 18:00
Location: Theater
8th Session Clinical Trials Part 2, Symptomatic Therapies
Systemic disease-modifying options for EB: use of losartan and ABCB5+ mesenchymal stem cells
Currently tested agents for itch relief
Challenges and Updates on EBS Clinical Trials
Oleogel-S10 real life experience
TCP-25, an immunomodulatory peptide in phase 2/3 clinical development targeting dysregulated inflammation in EB wounds
Oral abstract: Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa (GOTAS-ELK-EB)
Oral abstract: Repurposed treatment with losartan in children with severe forms of epidermolysis bullosa: effect on nutritional, growth, and hematological parameters, and iScorEB
Mariana Rivera Salazar
Discussion
all speakers
start: 18:00
end: 18:45
Location: Theater
Special Closing Session: Harnessing global policies for improved healthcare access
A policy-focused panel discussion on the integration of EB in the planning of national healthcare and social services worldwide; leveraging recent international policy frameworks (Universal Health Coverage, the UN Resolution on Rare Diseases, and the recent WHA Resolutions on Rare Diseases, Skin Diseases, and Diagnostics) and policy models in countries with advanced EB care and health access.
Antoine Daher
Mariangela Pellegrini
start: 19:00
end: 20:30
Poster Viewing Session Day 2: Networking and drink